CIDARA THERAPEUTICS INC: federal contracts won
Federal contracts of $10,000 or more awarded to this company since October 2023 (FY2024), from USAspending.gov. UEI: FKP3JZ9RUNY9
1contracts won
$58,051,983total obligated
$58,051,983median contract
Sep 30, 2025most recent start
Agencies it works for
| Agency | Contracts | Obligated |
|---|---|---|
| Department of Health and Human Services | 1 | $58,051,983 |
Industries (NAICS)
| NAICS | Contracts | Obligated |
|---|---|---|
| 541714 Research and Development in Biotechnology (except Nanobiotechnology) | 1 | $58,051,983 |
Where it works
Recent contracts
| Contract | Winner | Agency | Obligated | Start |
|---|---|---|---|---|
| DEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED BY INFLUENZA
75A50125C00017 · NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) · San Diego, CA |
— | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response |
$58,051,983 Potential value: $339,189,481 |
Sep 30, 2025 Ends: Sep 29, 2027 |
Source: USAspending.gov (prime contract awards of $10,000 or more). Values are amounts obligated to date. Recent months can still change as agencies report late.